BRPI0910622A2 - ANTICORPOS CONTRA FcRn E USOS DOS MESMOS - Google Patents

ANTICORPOS CONTRA FcRn E USOS DOS MESMOS Download PDF

Info

Publication number
BRPI0910622A2
BRPI0910622A2 BRPI0910622-7A BRPI0910622A BRPI0910622A2 BR PI0910622 A2 BRPI0910622 A2 BR PI0910622A2 BR PI0910622 A BRPI0910622 A BR PI0910622A BR PI0910622 A2 BRPI0910622 A2 BR PI0910622A2
Authority
BR
Brazil
Prior art keywords
antibody
fcrn
variable domain
domain sequence
binding
Prior art date
Application number
BRPI0910622-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Tenhoor Christopher
Muruganandam Arumugam
Charles Ladner Robert
Wood Clive
J. Bitonti Alan
Stattel James
Mcdonnell Kevin
Liu Liming
Dumont Jennifer
Sato Aaron
Original Assignee
Dyax Corp.
Biogen Idec Hemophilia Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp., Biogen Idec Hemophilia Inc. filed Critical Dyax Corp.
Publication of BRPI0910622A2 publication Critical patent/BRPI0910622A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
BRPI0910622-7A 2008-04-25 2009-04-24 ANTICORPOS CONTRA FcRn E USOS DOS MESMOS BRPI0910622A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4815208P 2008-04-25 2008-04-25
US61/048.152 2008-04-25
US4850008P 2008-04-28 2008-04-28
US61/048.500 2008-04-28
PCT/US2009/002536 WO2009131702A2 (en) 2008-04-25 2009-04-24 Antibodies against fcrn and use thereof

Publications (1)

Publication Number Publication Date
BRPI0910622A2 true BRPI0910622A2 (pt) 2020-03-10

Family

ID=41203902

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0910622-7A BRPI0910622A2 (pt) 2008-04-25 2009-04-24 ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
BR122021026834-7A BR122021026834B1 (pt) 2008-04-25 2009-04-24 Anticorpos isolados que se ligam a fcrn, composição farmacêutica que compreende os mesmos e métodos para detectar e para modular fcrn

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122021026834-7A BR122021026834B1 (pt) 2008-04-25 2009-04-24 Anticorpos isolados que se ligam a fcrn, composição farmacêutica que compreende os mesmos e métodos para detectar e para modular fcrn

Country Status (17)

Country Link
US (10) US8273351B2 (enExample)
EP (3) EP3670538A1 (enExample)
JP (5) JP6106854B2 (enExample)
KR (4) KR102072896B1 (enExample)
CN (3) CN108467431A (enExample)
AU (1) AU2009238605B2 (enExample)
BR (2) BRPI0910622A2 (enExample)
CA (2) CA3131470A1 (enExample)
ES (1) ES2650804T3 (enExample)
HK (1) HK1207089A1 (enExample)
IL (2) IL208846A (enExample)
MX (1) MX2010011679A (enExample)
NZ (1) NZ589451A (enExample)
SG (3) SG10202105499WA (enExample)
TW (3) TWI593423B (enExample)
WO (1) WO2009131702A2 (enExample)
ZA (1) ZA201007873B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI593423B (zh) 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
PH12013502378A1 (en) 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
SG11201401102VA (en) * 2011-09-30 2014-09-26 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
CA3233142A1 (en) 2011-11-30 2013-06-06 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
WO2013162050A1 (ja) 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
HRP20201422T1 (hr) * 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
EP2970406B1 (en) 2013-03-15 2017-12-13 Affibody AB New polypeptides
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
US20160075766A1 (en) * 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
PE20160674A1 (es) * 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
CA2934644C (en) * 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
EP3134733B1 (en) * 2014-04-25 2020-10-14 The Brigham and Women's Hospital, Inc. Assay and method for treating subjects with immune-mediated diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
NZ726089A (en) * 2014-04-30 2017-12-22 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
JP6568207B2 (ja) * 2014-05-19 2019-08-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒツジｂ細胞を用いて抗体を産生するための方法およびその使用
US10323066B2 (en) 2014-09-17 2019-06-18 Affibody Ab Neonatal Fc receptor binding dimer and methods of use
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10202007232WA (en) 2015-01-30 2020-09-29 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
HK1251483A1 (zh) * 2015-05-12 2019-02-01 Synt免疫公司 人源化亲和力成熟的抗fcrn抗体
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
US10900965B2 (en) 2015-08-24 2021-01-26 University Of Cincinnati Methods and compositions for the detection of Fc receptor binding activity of antibodies
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
LT3491025T (lt) * 2016-07-29 2023-11-27 Momenta Pharmaceuticals, Inc. Fcrn antikūnai ir jų panaudojimo būdai
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
US11041014B2 (en) 2016-10-28 2021-06-22 S & K Biopharma, Inc. Lactoferrin/albumin fusion protein and production method therefor
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
SG11201911832PA (en) * 2017-06-15 2020-01-30 UCB Biopharma SRL Method for the treatment of immune thrombocytopenia
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
EP3723802A1 (en) * 2017-12-13 2020-10-21 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
EP3802590A2 (en) 2018-06-08 2021-04-14 Argenx BVBA Compositions and methods for treating immune thrombocytopenia
UA130214C2 (uk) * 2018-07-20 2025-12-24 Момента Фармасьютикалз, Інк. Фармацевтична композиція антитіл проти fcrn
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
SG11202104373YA (en) * 2018-10-31 2021-05-28 Bioatla Inc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN114096562B (zh) 2019-05-15 2025-02-21 中外制药株式会社 抗原结合分子、药物组合物和方法
EP3980063A1 (en) 2019-06-07 2022-04-13 Argenx BVBA Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
CN114630678A (zh) * 2019-08-01 2022-06-14 詹森生物科技公司 FcRn抗体及其使用方法
KR20220148804A (ko) 2020-01-08 2022-11-07 아르젠엑스 비브이 천포창 장애의 치료 방법
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
KR102507515B1 (ko) * 2020-08-26 2023-03-08 이화여자대학교 산학협력단 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
WO2023030501A1 (zh) * 2021-09-03 2023-03-09 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
JP2025522251A (ja) 2022-05-30 2025-07-15 ハナル バイオファーマ カンパニーリミテッド 安定性が向上した抗ＦｃＲｎ抗体またはこの抗原結合断片
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE
CN115645537A (zh) * 2022-10-25 2023-01-31 成都臻拓医药科技有限公司 FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途
CN116047054A (zh) * 2023-03-08 2023-05-02 江西赛基生物技术有限公司 用于检测血小板抗体的试剂盒及其制备方法和使用方法
WO2025099576A1 (en) * 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
GB202318512D0 (en) * 2023-12-04 2024-01-17 argenx BV Methods of determining potency

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
DE2901218A1 (de) 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab Ung von theophyllin
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE81724T1 (de) 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5179107A (en) 1990-09-07 1993-01-12 Schering Corporation Antiviral quinolinone compounds
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE279947T1 (de) * 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
DK0971946T3 (da) 1997-01-21 2006-10-30 Gen Hospital Corp Selektion af proteiner ved anvendelse af RNA-protein-fusioner
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
EP1068356B8 (en) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6960178B2 (en) 2000-02-02 2005-11-01 Xepmed, Inc. Apparatus for enhanced plasmapheresis and methods thereof
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
EP1660128A4 (en) 2003-08-08 2009-01-21 Univ New York State Res Found ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
US20100266530A1 (en) * 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
US20090092507A1 (en) * 2005-08-05 2009-04-09 Ramirez Jr Emilio A Fluid pump systems
JP2009524664A (ja) * 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
TWI593423B (zh) 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
PH12013502378A1 (en) * 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
MX2020005981A (es) * 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
EP3802590A2 (en) * 2018-06-08 2021-04-14 Argenx BVBA Compositions and methods for treating immune thrombocytopenia
JP2022532229A (ja) * 2019-05-17 2022-07-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド 天疱瘡及び類天疱瘡疾患の治療における抗ＦｃＲｎ抗体の使用

Also Published As

Publication number Publication date
ZA201007873B (en) 2012-02-29
ES2650804T3 (es) 2018-01-22
SG10201804513WA (en) 2018-07-30
CA3131470A1 (en) 2009-10-29
CA2722082A1 (en) 2009-10-29
SG10202105499WA (en) 2021-07-29
KR20160079912A (ko) 2016-07-06
HK1160868A1 (en) 2012-08-17
EP2310415A2 (en) 2011-04-20
CN102149729B (zh) 2014-08-20
IL241091B (en) 2018-02-28
US20140248287A1 (en) 2014-09-04
WO2009131702A2 (en) 2009-10-29
TW201010720A (en) 2010-03-16
IL241091A0 (en) 2015-11-30
EP3670538A1 (en) 2020-06-24
KR20170122286A (ko) 2017-11-03
CN104479017A (zh) 2015-04-01
TW201630626A (zh) 2016-09-01
KR101837329B1 (ko) 2018-03-09
HK1207089A1 (en) 2016-01-22
BR122021026834B1 (pt) 2022-11-08
JP5989159B2 (ja) 2016-09-07
JP2011523351A (ja) 2011-08-11
JP6499132B2 (ja) 2019-04-10
KR20190104432A (ko) 2019-09-09
WO2009131702A9 (en) 2010-09-23
NZ589451A (en) 2012-07-27
JP2017029149A (ja) 2017-02-09
US20090324614A1 (en) 2009-12-31
KR102072896B1 (ko) 2020-02-03
IL208846A0 (en) 2011-01-31
SG196839A1 (en) 2014-02-13
AU2009238605B2 (en) 2014-11-06
CN108467431A (zh) 2018-08-31
AU2009238605A1 (en) 2009-10-29
IL208846A (en) 2015-09-24
EP2310415B8 (en) 2017-12-13
TWI547287B (zh) 2016-09-01
US20160222110A1 (en) 2016-08-04
TWI453031B (zh) 2014-09-21
EP3348573A1 (en) 2018-07-18
TW201509430A (zh) 2015-03-16
US8815246B2 (en) 2014-08-26
JP2019162105A (ja) 2019-09-26
US8273351B2 (en) 2012-09-25
US20160222112A1 (en) 2016-08-04
KR101634719B1 (ko) 2016-06-29
US20160194397A1 (en) 2016-07-07
EP2310415B1 (en) 2017-10-11
US20130045218A1 (en) 2013-02-21
JP2022115960A (ja) 2022-08-09
TWI593423B (zh) 2017-08-01
KR20110044729A (ko) 2011-04-29
WO2009131702A3 (en) 2010-02-18
MX2010011679A (es) 2011-05-23
US20160222108A1 (en) 2016-08-04
JP2015143230A (ja) 2015-08-06
US20160222111A1 (en) 2016-08-04
US20130078262A1 (en) 2013-03-28
US9260520B2 (en) 2016-02-16
EP3348573B1 (en) 2020-04-22
CN102149729A (zh) 2011-08-10
CA2722082C (en) 2021-11-09
JP6106854B2 (ja) 2017-04-05
US20160222109A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
JP6499132B2 (ja) ＦｃＲｎに対する抗体及びその使用
ES2748583T3 (es) Proteínas de unión al receptor Fc
AU2015200004B2 (en) Antibodies against fcrn and use thereof
HK40031845A (en) Antibodies against fcrn and use thereof
HK1156636B (en) Antibodies against fcrn and use thereof
HK1156636A (en) Antibodies against fcrn and use thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: DYAX CORP. (US) ; BIOGEN IDEC HEMOPHILIA INC. (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870200056205 DE06/05/2020, E NECESSARIO ESCLARECER A DIVERGENCIA QUE HA ENTRE O ENDERECO APRESENTADO NAPETICAO SUPRA E O ATUAL ENDERECO DA REQUERENTE, CONFORME PETICAO 020100099358 DE 22/10/2010

B25D Requested change of name of applicant approved

Owner name: DYAX CORP. (US) ; BIOVERATIV THERAPEUTICS INC. (US)

B25G Requested change of headquarter approved

Owner name: DYAX CORP. (US) ; BIOVERATIV THERAPEUTICS INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: BIOVERATIV THERAPEUTICS INC. (US) ; TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/04/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.